Oncologic outcomes of transoral laser microsurgery for T 3 laryngeal carcinoma : a meta-analysis
Hong Zhou,Dan-feng Li,Changtai Zhu
2018-01-01
Abstract:Laryngeal carcinomas are the second most common type of head and neck tumors, most of which are squamous cell carcinomas. The specific choice of treatment of T3 laryngeal (glottic or supraglottic) squamous cell carcinoma has been rather controversial. The aim of this study was to evaluate the efficacy and oncologic outcomes of transoral laser microsurgery (TLM) for untreated T3 laryngeal carcinoma. This study searched and screened all publications about TLM for untreated T3 laryngeal carcinoma in PubMed, EMBASE, Cochrane Library, and clinical trials. Retrieval cut-off date was May 31, 2017. Quality of studies was assessed and relevant data were extracted through inclusion and exclusion criteria. Seven studies were included in this meta-analysis. Pooled oncologic outcomes of patients with T3 glottic carcinoma, including 5-year overall survival (OS), 5-year disease-specific survival (DSS), and 5-year laryngectomy-free survival (LFS) rates, were 63% (95% confidence internal [CI], 57-69), 80% (95% CI, 65-92), and 77% (95% CI, 63-88), respectively. Pooled oncologic outcomes of patients with T3 supraglottic carcinoma, including 5-year OS, DSS, and LFS rates, were 68% (95% CI, 52-82), 80% (95% CI, 65-92), and 90% (95% CI, 79-97), respectively. Pooled ORs for 5-year OS, DSS, and LFS between glottic carcinoma and supraglottic carcinoma were 0.84 (95% CI, 0.35-2.01), 0.88 (95% CI, 0.27-2.85), and 0.33 (95% CI, 0.20-0.56), respectively. In conclusion, TLM offers patients with T3 glottic or supraglottic carcinomas better oncologic outcomes. TLM may be a valid option for organ-preserving surgery. However, its efficacy should be confirmed by more prospective clinical trials.